Concepedia

Cost–effectiveness of overactive bladder treatments: from the US payer perspective

Brian Murray, Sam Hessami, Dmitry Gultyaev, J. Lister, Roger R. Dmochowski, Kristin Khalaf Gillard, Sanja Stanisic, Amy Tung, Steven A. Kaplan

Journal of Comparative Effectiveness Research · 2018 · 35 citations · 25 references

DOIFull text

Open access

Abstract

Compared with BSC, onabotA 100U was the most cost-effective treatment option for patients with refractory OAB.

References

25

Markov Models in Medical Decision Making

Frank A. Sonnenberg, J. Robert Beck · Medical Decision Making · 1993 · 2.4K citations

, , +21

Prevalence and burden of overactive bladder in the United States

Walter F. Stewart, J. Van Rooyen, Geoffrey W. Cundiff et al. · World Journal of Urology · 2003 · 2.2K citations · Full text

, , +5

Diagnosis and Treatment of Overactive Bladder (Non-Neurogenic) in Adults: AUA/SUFU Guideline

E. Ann Gormley, Deborah J. Lightner, Kathryn L. Burgio et al. · The Journal of Urology · 2012 · 697 citations

Randomized Trial of Percutaneous Tibial Nerve Stimulation Versus Sham Efficacy in the Treatment of Overactive Bladder Syndrome: Results From the SUmiT Trial

Kenneth M. Peters, Donna J. Carrico, Ramon Perez-Marrero et al. · The Journal of Urology · 2010 · 470 citations

OnabotulinumtoxinA 100 U Significantly Improves All Idiopathic Overactive Bladder Symptoms and Quality of Life in Patients with Overactive Bladder and Urinary Incontinence: A Randomised, Double-Blind, Placebo-Controlled Trial

Christopher R. Chapple, Karl‐Dietrich Sievert, Scott MacDiarmid et al. · European Urology · 2013 · 401 citations

, , +5